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Summary
BACKGROUND: In clinical practise the high dose ACTH
stimulation test (HDT) is frequently used in the assessment
of adrenal insufficiency (AI). However, there is uncertainty
regarding optimal time-points and number of blood
samplings. The present study compared the utility of a
single cortisol value taken either 30 or 60 minutes after
ACTH stimulation with the traditional interpretation of the
HDT.
METHODS: Retrospective analysis of 73 HDT performed
at a single tertiary endocrine centre. Serum cortisol was
measured at baseline, 30 and 60 minutes after intravenous
administration of 250 µg synthetic ACTH1–24. Adrenal in-
sufficiency (AI) was defined as a stimulated cortisol level
<550 nmol/l.
RESULTS: There were twenty patients (27.4%) who
showed an insufficient rise in serum cortisol using tra-
ditional HDT criteria and were diagnosed to suffer from
AI. There were ten individuals who showed insufficient
cortisol values after 30 minutes, rising to sufficient levels
at 60 minutes. All patients revealing an insufficient cortisol
response result after 60 minutes also had an insufficient
result after 30 minutes. The cortisol value taken after 30
minutes did not add incremental diagnostic value in any
of the cases under investigation compared with the 60
minutes’ sample.
CONCLUSIONS: Based on the findings of the present ana-
lysis the utility of a cortisol measurement 30 minutes after
high dose ACTH injection was low and did not add incre-
mental diagnostic value to a single measurement after 60
minutes.
Key words: ACTH stimulation test; stimulated serum
cortisol; adrenal insufficiency
Introduction
Despite many attempts at improvement, the diagnosis of
adrenal insufficiency remains a challenge and is, conse-
quently, often delayed [1]. While a variety of diagnostic
methods are presently available (e.g insulin tolerance test,
metyrapone test, high dose ACTH stimulation test, Low
dose ACTH stimulation test, morning cortisol value), there
is an ongoing discussion on which test to use preferably
[2–6]. While the insulin tolerance test (ITT) has been sug-
gested to represent a gold standard, it has a number of con-
traindications, requires close supervision, and is, therefore,
demanding for patients and medical staff [2, 7].
The ACTH stimulation test offers a less complex altern-
ative to the ITT. While historically, it has been debated
whether low-dose ACTH stimulation may have advantages
over the high-dose stimulation test (HDT), the current lit-
erature does not support this notion anymore [8–11]. As a
consequence, the HDT is well established in many centres
for specific indications and has been shown to provide a re-
liable prognostic accuracy in the diagnosis of adrenal insuf-
ficiency [6, 12, 13]. The test is comparably easy to perform,
has been shown to be cost-effective and is well tolerated by
the majority of patients [7].
In general the protocol for the HDT encompasses blood
samples for cortisol at time-points 0, 30, and 60 minutes
after administering 250µg of synthetic ACTH1–24 [12, 14].
However, there is uncertainty about whether the diagnosis
of AI based on HDT may be facilitated by focussing on a
single cortisol value, thereby potentially further reducing
associated resources. Previous studies have suggested that
a single value taken after 30 minutes may adequately re-
flect adrenocortical response [2, 6, 13, 15]. Other reports
conversely found the value after 60 minutes to provide an
accurate predictor of adrenal function [4, 16, 17]. Such dis-
crepancies may at least be partially explained by differen-
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ces in study participants (e.g., age, ethnicity, etc.) as well as
by underlying pathologies.
The aim of the present study was to assess whether cortisol
measurement 30 minutes after HDT provides additional
diagnostic value over a single sample after 60 minutes in
the evaluation of AI in a Caucasian population.
Methods
Study design and patients
This was a retrospective single-centre study at a tertiary en-
docrine referral centre. All procedures were carried out in
accordance with the local ethical guidelines and informed
consent was obtained for each test.
Data of all consecutive HDT performed between January
2012 and August 2013 at the Division of Endocrinology,
Diabetes and Clinical Nutrition of the University Hospital
of Bern (Inselspital), Switzerland were analysed.
HDT was not performed less than 3 months after interven-
tion in patients with pituitary surgery and not less than 24
months after intervention in case of radiotherapy for pitu-
itary disease. In case of an ongoing glucocorticoid replace-
ment therapy (e.g. due to suspected but not confirmed AI)
all patients were switched to hydrocortisone prior to the
HDT to avoid interference due to longer half-life of oth-
er compounds (e.g., prednisone, dexamethasone, etc.) and
hydrocortisone was stopped at least 12 hours before test-
ing. In case of pituitary disease, deficiencies of addition-
al hypothalamic-pituitary axis hormones had to be under
stable and adequate replacement therapy.
HDT protocol
Total serum cortisol was measured at baseline as well as
30, and 60 minutes after intravenous administration of 250
µg synthetic ACTH1–24 (Synacthen, Novartis Pharma Sch-
weiz AG, Switzerland). Determination of cortisol was per-
formed using the Roche Modular Analytics E170 elec-
trochemiluminescence immunoassay (Roche Diagnostics,
Rotkreuz, Switzerland). The intra- and inter-assay coeffi-
cients of variation were 1.7% and 1.8%, the recovery with-
in 90–110% of serum value.
Statistical methods
Values are expressed as mean ± standard deviation (SD),
unless otherwise specified. After testing for normal dis-
tribution (Shapiro-Wilk Test and Q-Q plots), continuous
variables were analysed for significant differences by two-
tailed t tests or ANOVA. In case of repeated measures
a repeated-measure-ANOVA model was used and
Bonferroni-correction was applied to correct for multiple
comparison. We used a cut off level of 550 nmol/l to define
AI, i.e., serum levels <550 nmol/l were interpreted as AI
[2]. A p-value <0.05 was considered statistically signific-
ant. All analyses were performed using Stata 12.1 (Stata
Corporation, College Station, TX, USA).
Results
A total of 73 individuals with suspected adrenal insuffi-
ciency (40 female and 33 male patients) were included in
the analysis. Mean age was 51.2 ± 16.2 years. The indic-
ation for the ACTH stimulation test was a suspicion of
primary adrenal disease in 9 (12.3%), suspected second-
ary (e.g., hypothalamic or pituitary) AI in 26 (35.6%), AI
due to exogenous corticosteroids in 27 (37%), and other in-
dications (e.g., unspecific symptoms like fatigue, dizziness,
etc.) in 11 (15.1%) of the patients, respectively (table 1).
Of the 73 patients 34 (46.6%) had received glucocorticoid-
replacement therapy with an average hydrocortisone equi-
valent dose of 14.5 ± 9.6 mg per day in the period before
the test. The main reasons for pre-existing glucocorticoid
therapy were either pre-emptive temporary coverage after
pituitary surgery or radiotherapy (e.g., until formal testing),
or permanent glucocorticoid treatment due to an underlying
disease (e.g., chronic inflammatory disease, rheumatoid
disorders, etc.).
Figure 1 depicts cortisol values before and after ACTH
stimulation. In 20 of the 73 patients (27.4%) an AI was
diagnosed based on the results of HDT (using either of
the available measurements). Mean serum cortisol levels at
baseline (immediately before ACTH injection) were 165.5
± 110.4 nmol/l for patients suffering from AI and 346.2 ±
118.2 nmol/l for patients with intact adrenal function (NO),
respectively (p <0.001). At 30 minutes after ACTH stimu-
lation mean cortisol values were 332.3 ± 151.7 nmol/l for
AI patients and 662.6 ± 119.8 nmol/l for NO, respectively
(p <0.001). At 60 minutes after ACTH mean cortisol was
383.8 ± 158.2 nmol/l for AI patients and 778.7 ± 144.3
nmol/l for NO, respectively (p <0.001).
Figure 2 a-c depict the cortisol values of all included in-
dividuals at time points 0, 30, and 60 minutes after in-
jection of ACTH. Figure 2a shows the results of individu-
als where all measurements were consistently <550 nmol/
l. Figure 2b shows the results of those individuals where
cortisol values were ≥550 nmol/l at both time-points (30
and 60 minutes). Figure 2c finally depicts the cortisol val-
ues of those individuals with discrepant results at 30 and
60 minutes (e.g., where the 30 minute result was <550
nmol/l but where the 60 minute value was ≥550 nmol/l). In
none of the 73 individuals would the cortisol value taken
Figure 1
Cortisol values immediately before (0 min = baseline) and 30
minutes (30 min) and 60 minutes (60 min) after ACTH injection.
Patients with adrenal insufficiency (AI) are plotted in dark grey;
patients with normal adrenal function (NO) are plotted in light grey. *
p <0.001 for comparison with baseline values.
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30 minutes after ACTH have added incremental diagnost-
ic value to the interpretation of the HDT. Conversely, if
interpretation of the HDT results had been based on the
30 minute cortisol value, exclusively, 10 out of 73 patients
would have been diagnosed with AI although reaching suf-
ficient cortisol levels 60 minutes after stimulation.
Discussion
The main finding of the present analysis is that a cortisol
measurement taken 30 minutes after stimulation with a
high dose of ACTH does not offer additional diagnostic
value in the diagnosis of AI. As a consequence, if HDT is
chosen to evaluate a patient with potential AI in clinical
practise, the present results suggest that the HDT protocol
may be simplified to a single cortisol measurement 60
minutes after ACTH stimulation, thereby reducing labour
and costs. Conversely, restricting the analysis to a single
value after 30 minutes would have translated into a sub-
stantial misclassification of patients.
The present findings are well in line with a retrospective
study performed in South Asian patients [17] as well as
a recent analysis investigating Caucasian individuals [16].
Similarly to the present analysis Chitale et al. found a sig-
nificant proportion of patients being inappropriately dia-
gnosed to suffer from AI if decisions were based on the
30 minute sample, exclusively, while no individual was
found to pass the 30 minute sampling and to fail at 60
minutes [16]. These considerations go along with earlier
studies investigating the kinetics of peak-cortisol response
after ACTH administration, showing an early cortisol rise
within the first 30 minutes, however followed by an addi-
tional increase between 30 and 60 minutes after ACTH in-
jection [8, 16, 18–21].
While the gold standard in the diagnosis of AI may still be
attributed to the ITT [1], this test is time-consuming and
potentially cumbersome for patients and investigators. Fur-
thermore, there are several contraindications for the ITT (as
for instance coronary artery disease or seizure disorders).
Indeed, the indication to perform HDT in the present study
was essentially the presence of accepted contraindications
to ITT or refusal of patients to undergo more invasive test-
ing. Of note, the HDT has been validated against the ITT
in numerous studies generally revealing a high agreement
[13, 15, 18, 22–24]. As a consequence, and despite the
well-known fact there are some reports showing discrepan-
cies between results of the ITT and HDT [15, 23], espe-
cially in case of secondary AI [12], the HDT is an accepted
screening method for AI due to its advantages in feasibility
and comparably low associated risks. Interestingly, stud-
ies comparing the findings in the ITT with cortisol values
taken 60 minutes after ACTH stimulation reported similar
correlation as for the values after 30 minutes [8, 21]. Dis-
crepant findings in studies comparing ITT to HDT may be
ascribed to different cortisol assays, varying cut off values,
as well as different patients under investigation (e.g., pre-
test probability, ethnicity, etc). In general, for HDT cortisol
cut off levels between 500–600 nmol/l are chosen [4, 12,
25]. Raising the cut off level would improve the sensitiv-
ity of the test, however, by simultaneously increasing the
risk of false positive results, translating into over-diagnos-
is and over-treatment [12, 13, 16]. As a consequence, the
present study used a widely accepted cut off level of 550
nmol/l [2, 16, 23, 26]. Of importance, the present study was
performed in a mixed patient population of a tertiary endo-
crine referral centre encompassing both individuals with a
suspicion of primary (adrenal) as well as secondary (central
or exogenous) AI. Although one may criticise that this may
reduce generalisability of the present findings, this also re-
flects daily clinical practise. And it is noteworthy that an
incremental value of the 30 minute sample could not been
found in any of the potential subgroups. We are entirely
aware that results of HDT must be interpreted with caution
in patients after pituitary surgery or radiotherapy due to
pituitary disease, and testing should not be performed dir-
ectly after such interventions since accuracy may be sub-
stantially reduced for secondary AI [12]. However, if HDT
is performed later in the follow-up previous reports have
corroborated high predictive values in excluding clinic-
ally significant secondary AI, thereby again recommending
HDT as a primary screening test also for secondary AI [2,
13]. As a consequence, the present study was careful not
to perform HDT less than 3 months after pituitary surgery
and not less than 24 months after pituitary irradiation ther-
apy, thereby minimising confounding. Still, it has to be em-
phasised that if AI is still clinically suspected after a first
negative HDT result, other stimulation tests (ITT, Metyra-
pone) should clearly be added to detect possible false neg-
ative HDT results [1, 12–14].
We acknowledge several limitations concerning the present
study. First, analyses were based on retrospective data and
will formally have to be validated in an independent pro-
Table 1: Patient characteristics
Total NO AI p-value
Tests (n) 73 53 (72.6%) 20 (27.4%)
Age (y) 51.2±16.2 49.9±16.5 54.7±15.4 0.26
BMI (kg/m2) 27.9±5.8 27.7±6.7 28.3±3.4 0.71
Sex
M
F
33 (45.2%)
40 (54.8%)
21 (39.6%)
32 (60.4%)
12 (60%)
8 (40%)
0.12
Test-indication
primary ins.
second. ins.
exog. GC
other
9 (12.3%)
26 (35.6%)
27 (37%)
11 (15.1%)
8 (15%)
19 (35.9%)
17 (32.1%)
9 (17%)
1 (5%)
7 (35%)
10 (50%)
2 (10%)
0.48
NO, normal adrenal function; AI, adrenal insufficiency; BMI, body mass index; m, male; f, female; test-indication, purpose of test based on the presumed diagnosis; primary
ins., primary adrenal insufficiency; second. ins., secondary adrenal insufficiency (=central adrenal insufficiency); exog. CG, exogenous glucocorticosteroid medication
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spective set of individuals. Second, the aim of the study
was not to compare the diagnostic value of the HDT against
other test modalities but solely to assess whether a cortisol
measurement 30 minutes after HDT provides additional
diagnostic value over a single sample after 60 minutes. To
further substantiate these findings, a validation against an
external gold standard (e.g. ITT) would be highly inter-
esting and valuable. However, if in a clinical situation the
HDT is chosen as a diagnostic tool in the evaluation of
AI, then the present data at least suggest that independent
of correlations with ITT or other test modalities the HDT
protocol may potentially be simplified. Third, the present
study encompassed a mixed patient population at a tertiary
endocrine referral centre including individuals with suspec-
Figure 2
Individual cortisol values at time points 0, 30, and 60 minutes after
injection of ACTH; grouped by patients with adrenal insufficiency
(fig. 2a), normal adrenal function (fig. 2b) and patients with
discrepant adrenal response at 30 and 60 minutes (fig. 2c).
ted adrenal as well as central AI or AI secondary to exogen-
ous glucocorticoids. As a consequence our findings apply
to these patient characteristics, exclusively, and generalis-
ability is clearly restricted. On the other hand, the findings
of the present study are applicable to all subgroups. In ad-
dition, the study was performed at one institution with the
identical medical investigators over the entire study peri-
od, applying accepted diagnostic cut off values, and using
comparably strict inclusion criteria for patients with suspi-
cion of central AI (e.g., time period between interventions
and testing), as well as in those with exogenous glucocor-
ticoids (e.g., withholding hydrocortisone for a defined peri-
od). Finally, we used a HDT protocol and no statements can
be made on the validity of either cortisol measurement after
the application of lower doses of ACTH since this was not
the focus of the present study.
In conclusion, the present results suggest that a cortisol
measurement taken 30 minutes after stimulation with a
high dose of ACTH does not offer additional diagnostic
value in the diagnosis of AI as compared to a single meas-
urement after 60 minutes. As a consequence, if HDT is
chosen to evaluate a specific patient with potential AI in
clinical practise, the present results suggest that the HDT
protocol may be simplified to a single cortisol measure-
ment 60 minutes after ACTH stimulation, thereby reducing
labour and costs.
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Figures (large format)
Figure 1
Cortisol values immediately before (0 min = baseline) and 30 minutes (30 min) and 60 minutes (60 min) after ACTH injection. Patients with
adrenal insufficiency (AI) are plotted in dark grey; patients with normal adrenal function (NO) are plotted in light grey. * p <0.001 for comparison
with baseline values.
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Figure 2
Individual cortisol values at time points 0, 30, and 60 minutes after injection of ACTH; grouped by patients with adrenal insufficiency (fig. 2a),
normal adrenal function (fig. 2b) and patients with discrepant adrenal response at 30 and 60 minutes (fig. 2c).
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